Regenerative Medical Technology (RMTG) Income from Continuing Operations (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Income from Continuing Operations of 1960766.0 for Q1 2026, down 157.69% year-over-year from 3398575.9 in Q1 2025, and up 15.26% quarter-over-quarter from 2313871.0 in Q4 2025.
Regenerative Medical Technology (RMTG) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 1960766.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 157.69% year-over-year to 1960766.0; the TTM figure through Mar 2026 stood at 9516817.0 (down 118.19% YoY), while the FY2025 annual figure was 8581976.0, down 44.8% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1960766.0, up from 2313871.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4722849.0 in Q4 2023, with the low at 3936723.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 1496800.0 (2022), against an average of 1225939.24.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations soared 292.21% in 2023, then sank 378.81% in 2024.
- Regenerative Medical Technology's Income from Continuing Operations stood at 2457154.0 in 2022, then jumped by 292.21% to 4722849.0 in 2023, then plunged by 113.53% to 639071.0 in 2024, then plunged by 262.07% to 2313871.0 in 2025, then grew by 15.26% to 1960766.0 in 2026.
- Business Quant data shows RMTG's Income from Continuing Operations at 1960766.0 in Q1 2026, 2313871.0 in Q4 2025, and 3936723.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | -1.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.96 Mn |
| Dec 31, 2025 | -2.31 Mn |
| Sep 30, 2025 | -3.94 Mn |
| Jun 30, 2025 | -1.31 Mn |
| Mar 31, 2025 | -760,890.00 |
| Dec 31, 2024 | -639,071.00 |
| Sep 30, 2024 | -885,924.00 |
| Jun 30, 2024 | -2.08 Mn |
| Mar 31, 2024 | -1.96 Mn |
| Dec 31, 2023 | 4.72 Mn |
| Sep 30, 2023 | -1.73 Mn |
| Jun 30, 2023 | -433,555.00 |
| Mar 31, 2023 | -577,763.00 |
| Dec 31, 2022 | -2.46 Mn |
| Sep 30, 2022 | -1.34 Mn |
| Jun 30, 2022 | -1.50 Mn |
| Mar 31, 2022 | -1.68 Mn |
| Dec 31, 2021 | 1.16 Mn |
| Sep 30, 2021 | -9.92 Mn |
| Jun 30, 2021 | -694,968.00 |